CrossMark

REVIEW ARTICLE

Oxidative stress in Alzheimer disease and mild cognitive impairment: evidence from human data provided by redox proteomics

Aaron M. Swomley[1] · D. Allan Butterfield[1]

Abstract Alzheimer disease (AD) is a neurodegenerative disease with many known pathological features, yet there is still much debate into the exact cause and mechanisms for progression of this degenerative disorder. The amyloid-beta (Aβ)-induced oxidative stress hypothesis postulates that it is the oligomeric Aβ that inserts into membrane systems to initiate much of the oxidative stress observed in brain during the progression of the disease. In order to study the effects of oxidative stress on tissue from patients with AD and amnestic mild cognitive impairment (MCI), we have developed a method called redox proteomics that identifies specific brain proteins found to be selectively oxidized. Here, we discuss experimental findings of oxidatively modified proteins involved in three key cellular processes implicated in the pathogenesis of AD progression: energy metabolism, cell signaling and neurotransmission, as well as the proteasomal degradation pathways and antioxidant response systems. These proteomics studies conducted by our laboratory and others in the field shed light on the molecular changes imposed on the cells of AD and MCI brain, through the deregulated increase in oxidative/nitrosative stress inflicted by Aβ and mitochondrial dysfunction.

Keywords Alzheimer disease · Mild cognitive impairment · Amyloid-beta · Reactive oxygen species · Redox proteomics

Abbreviations

3NT	3-Nitrotyrosine
AD	Alzheimer disease
Aβ	Amyloid-beta
CRMP2	Collapsin response mediator protein-2
EAD	Early-onset Alzheimer disease
ESI–MS/MS	Electrospray ionization tandem mass spectrometry
FAD	Familial Alzheimer disease
GSH	Glutathione
HNE	4-Hydroxynonenal
IPL	Inferior parietal lobule
LAD	Late-onset Alzheimer disease
MCI	Mild cognitive impairment
NFT	Neurofibrillary tangle
PC	Protein carbonyl
PCAD	Preclinical Alzheimer disease
PET	Positron emission tomography
Pin1	Peptidyl-prolyl *cis/trans* isomerase NIMA-interacting 1
PMI	Postmortem interval
RNS	Reactive nitrogen species
ROS	Reactive oxygen species
SP	Senile plaque
UCH L-1	Ubiquitin carboxy-terminal hydrolase L-1

Introduction

Alzheimer disease (AD) is a devastating neurodegenerative disease and the primary known cause of dementia. While there are many factors that go into the development of AD, the one primary risk factor is aging. It is important, however, to make the distinction between normal aging and AD as most individuals do not develop AD as a part of their

✉ D. Allan Butterfield
dabcns@pop.uky.edu; dabcns@uky.edu

1 Department of Chemistry and Sanders-Brown Center on Aging, University of Kentucky, Lexington, KY 40506-0055, USA

aging process, though as medicine continues to advance in effectiveness and the prolonging of the normal age span, the rate of AD development is expected to continue to increase (Hebert et al. 2003).

Alzheimer disease is clinically characterized by a loss of cognitive ability and short-term memory formation. Patients may be subjected to the Mini-Mental Status Examination (MMSE) if their clinician suspects abnormal cognitive performance. Pathologically, AD is a diverse and complex disease affecting nearly every subcellular system of the affected neurons (Oddo 2008; Tu et al. 2014; Moh et al. 2011; Wilkins et al. 2014). One primary pathological characteristic has been identified as being an accumulation of amyloid-beta 1–40 and 1–42 ($A\beta_{1-40}$ and $A\beta_{1-42}$) though the primary amyloidogenic product implicated in AD has been $A\beta_{1-42}$ (Glabe 2001; Walsh and Selkoe 2004). $A\beta$ has long been known to form extracellular agglomerations termed senile plaques (SPs), but more recently it has been found that the more toxic forms of $A\beta$ are not the insoluble (SPs) but rather more soluble $A\beta$ oligomers (Glabe 2005). It is these oligomers that are proposed to do the most oxidative damage to the cell, perhaps due to their ability to translocate into membrane systems such as the cell membrane and the mitochondrial membrane. Aside from $A\beta$, hyperphosphorylated tau has been shown to lead to microtubule destabilization and formation of neurofibrillary tangles (NFTs) (Braak and Braak 1997; Andreadis et al. 1992). NFTs are composed primarily of paired helical filaments of hyperphosphorylated tau, and the severity of an AD patient's dementia is correlated closely with NFT density (Braak and Braak 1997). The loss of tau and the subsequent destabilization of microtubules may play a large role in the pathogenesis of AD due to a loss in structural integrity and methods for intracellular trafficking of vesicles and organelles which rely in part on organized microtubule networks to function properly.

While $A\beta$ and NFTs have been the focus of the majority of AD research since its official recognition, there are many other systems, as previously discussed, that go awry in AD such as metabolism, insulin signaling, the proteostasis network, synaptic growth and maintenance, cell cycle control, and the antioxidant response system to name a few. While systems affected may at first seem disparate, there is a common unifying theme in oxidative/nitrosative stress and altered redox state of the cell (Butterfield et al. 2013).

Alzheimer disease can be further categorized into three primary and one alternate stagings: amnestic mild cognitive impairment (MCI), early-onset AD (EAD), late-stage AD (LAD), and preclinical AD, respectively. MCI is often referred to as the first stage or transition stage of AD, and it is the stage in which the patient and those around them begin to first notice signs of memory loss, yet not all patients with MCI transition to AD (Jicha et al. 2006). $A\beta$

load and NFT density increase in number and concentration through the progression of MCI to LAD, with LAD presenting with the highest loads and subsequently the lowest neuron density and highest cognitive impairment and ultimately death. PCAD is an unusual stage in which the patients has significant levels of $A\beta$ and NFT, yet perform normally in cognitive testing and activities of daily living (Bradley et al. 2010). PCAD has of late been the focus of experimentation for some in order to determine the differences in patient outcome, though PCAD is currently difficult to study due to the necessity to determine $A\beta$ and NFT density by PET scanning methods, so subjects are usually identified only after death from another means (Aluise et al. 2011).

Oxidative stress

The maintenance of the cellular redox state is of utmost importance in regard to not only the normal functioning of the cell, but more importantly its survivability. The basis of the cellular redox state is composed of molecules termed oxidants and reductants, based on their chemical ability to oxidize or reduce substrate molecules. Common oxidants known to participate in the redox state are molecules such as hydrogen peroxide (H_2O_2), superoxide (O_2^-), the hydroxyl anion (OH^-), the hydroxyl radical (OH), nitric oxide (NO), and peroxynitrite ($ONOO^-$) (Dasuri et al. 2013). Many diseases such as AD have been found to have a dysregulation of oxidant levels which have been implicated in the disease pathogenesis (Butterfield and Sultana 2011; Nourazarian et al. 2014; Indo et al. 2015; Tangvarasittichai 2015). This loss of homeostasis can both be attributed to an over-production of oxidants as well as a loss of antioxidants or the antioxidant defense system. Within the brain, the primary means of dealing with an excess of oxidants is the antioxidant glutathione (GSH) and its supporting enzymes, glutathione peroxidase (GPX), glutathione reductase (GR), and glutathione-S-transferase (GST). A dysregulation in the redox state of the cell if left unchecked leads to oxidant-induced damage of organelles, membranes, and biomolecules such as proteins, lipids, and nucleic acids (Fig. 1) (Dasuri et al. 2013; Uttara et al. 2009; Halliwell 2012; Valko et al. 2007).

One major source of oxidant generation in AD is from the functioning of the mitochondria during oxidative phosphorylation in which it produces ATP for the cell. Healthy mitochondria have been reported to leak superoxide radical anion as a natural part of its normal functioning due to the imperfect efficiency of electron transfer through the electron transport chain (Dasuri et al. 2013; Adam-Vizi 2005; Calabrese et al. 2005). This superoxide radical leak has also long been attributed to one of the primary theories of

Fig. 1 Proposed pathways involved in the production of ROS/RNS in Alzheimer disease that lead to protein oxidation/ nitration and lipid peroxidation

normal aging. However, as AD progresses and mitochondria are damaged, the normal efficiency of the mitochondria also deteriorates leading to a feed-forward mechanism of superoxide production (Friedland-Leuner et al. 2014). Superoxide in and of itself is a potent oxidant, yet it has its limitations, one being that it cannot easily cross into membrane systems due to its negative charge. However, some suggest that the H^+ within the intermembrane space of mitochondrion leads to HO_2, which, being neutral, can cross membranes (Hernandez-Saavedra and McCord 2007). In an attempt to rid the cell of superoxide, enzymes such as the mitochondrial-resident manganese superoxide dismutase (Mn-SOD) and the cytosolic copper/zinc-superoxide dismutase (Cu/Zn-SOD) reduce superoxide to hydrogen peroxide (Halliwell 2012). Hydrogen peroxide is a relatively weak oxidant; however, its lack of a dipole moment allows it to cross into and through membranes to other cellular compartments, whereas superoxide itself is essentially localized upon production. Hydrogen peroxide may also react with either copper (I) or iron (II) in a Fenton chemical reaction to produce the much more reactive hydroxyl radical that is accountable for much of the downstream damage of superoxide production (Halliwell and Gutteridge 1984). The production of hard nucleophiles such as hydroxyl radical leads directly to the damage of proteins and nucleotides.

The proper functioning of proteins is primarily the result of the integrity of its three-dimensional structure. Protein oxidation has implications for protein dysfunction or loss of function, depending on the severity and location of the oxidative damage to the protein (Butterfield 2002). Upon protein oxidation, proteins may lose their secondary and tertiary structural integrities which may lead to the exposure of hydrophobic amino acids to the protein surface causing aggregation and further unfolding and loss of activity (Dunlop et al. 2009; Dean et al. 1997). Direct oxidative insult to the peptide chain backbone may even result in fragmentation (Dean et al. 1997). The most common type of direct protein oxidation is that of protein carbonylation, in which an aldehyde or ketone is formed. Both the side chains of every amino acid along with the peptide backbone are susceptible to this form of oxidation, though the aromatic amino acids such as tryptophan and tyrosine are prone to generate hydroxy derivatives (Stadtman and Levine 2000). Among the more susceptible amino acids to oxidation are methionine and cysteine, with methionine being oxidized to form methionine sulfoxide (MeSOX) while the sulfhydryl group of cysteine may be oxidized to form disulfide bonds either intra or intermolecularly, though these forms of oxidation have their own enzymatic mechanisms of reversal (Dunlop et al. 2009). Moreover, cysteine can be oxidized to sulfenic (–SOH), sulfinic (–SOH_2), and sulfonic (–SOH_3) acids, the first being often reversible and involved in signaling (Wang et al. 2008; Nakamura et al. 2015).

Indirect protein oxidation may also occur in which the oxidant interacts with another molecule prior to an interaction with the actual protein (Suzuki et al. 2010). One common form of indirect protein oxidation is through the conjugation of reactive aldehydes to the protein. Reactive aldehydes such as acrolein or 4-hydroxynonenal (HNE) are α/β-unsaturated aldehydes which are the products of the lipid peroxidation of unsaturated fatty acids such as arachidonic acid. The brain is specifically prone to secondary carbonylation via lipid peroxidation due to the large concentrations of poly-unsaturated fatty acids (PUFAs) resident in brain tissue (Butterfield et al. 2010a, b). The process of lipid peroxidation is specifically toxic due to allylic hydrogen abstraction and subsequent radical chain reaction and propagation on acyl chains of polyphenols, processes that may spread between membrane systems and even adjacent cells (Butterfield et al. 2010a, b; Bader Lange et al. 2010; Castegna et al. 2004). Reactive aldehydes in the presence of nucleophilic protein side chains undergo Michael addition, resulting in indirect protein carbonylation. This covalent modification results in structural changes which likely results in protein activity and cause dysfunction (Perluigi et al. 2012).

Lipid peroxidation in the AD brain may be measured by the detection of elevated levels of free or protein-bound acrolein, HNE, isoprostane 8,12-iso-iPF$_2$α-VI, F$_2$-isoprostane (F$_2$-IsoP), and F$_4$-neuroprostane (F$_4$-NP) (Markesbery et al. 2005; Yao et al. 2003). A primary means of defense against lipid peroxidation products for the neuron is the ability of GSH to bind free HNE prior to reaction with a biomolecule of importance such as a protein (Lovell et al. 1998). Not only has it been shown that there was an increase in HNE-bound by GSH (HNE–GSH) in AD brain, but many of the enzymes responsible for the upkeep and maintenance of GSH levels, such as glutathione-S-transferase (GST) and multidrug-resistant protein-1 (MRP-1), were found to be modified by HNE themselves and subsequently a buildup of HNE-bound protein adducts (Lovell et al. 1998; Sultana and Butterfield 2004). This finding suggests that there is a significant increase in free and protein-bound HNE in AD which has overwhelmed the cells defense against reactive aldehydes. This deficiency in HNE clearance likely plays a role in HNE-modified proteins (Tables 1, 2, 3).

The detection of carbonylated proteins have had been simplified with the use of 2,4-dinitrophenylhydrazine (DNPH), which upon contact with a carbonyl may form a hydrazone, detectable through the use of immunochemical assay and antihydrazone adduct antibodies (Suzuki et al. 2010; Levine et al. 1994). Indirect carbonylation via reactive aldehyde addition is also detected immunochemically as well as through the use of spectrophotometry (Sayre et al. 1997; Lovell et al. 2001).

Nitric oxide is an important signaling molecule in regulating vascular smooth muscle relaxation, antixenobiotic

Table 1 Summary of metabolically involved proteins discussed within the text, modifications identified, and the AD stage and/or brain region analyzed

Identified protein	Modifications
ATP synthase	HNE, 3NT
Alpha-enolase	HNE, 3NT, PC
Aldolase	HNE, 3NT
Aconitase	HNE
Creatine kinase BB	PC
Phosphoglycerate mutase 1	PC
Carbonic anhydrase II	PC
Triose phosphate isomerase	3 NT, PC
Lactate dehydrogenase	HNE, 3NT
Phosphoglycerate-3-dehydrogenase	3NT
VDAC	3NT
Pyruvate kinase	HNE, PC
Phosphoglycerate kinase	HNE
Malate dehydrogenase	3NT
Glucose-regulated protein precursor	3NT

actions, and postsynaptic density functions, among other processes (Shinde et al. 2000; Xu et al. 1994). However, nitric oxide itself is also a free radical which may become toxic if its concentrations become too great (McCarty 2006). Nitric oxide when in the presence of superoxide may react to form peroxynitrite (ONOO$^-$), a reactive anion (Williamson et al. 2002). The reaction between nitric oxide and superoxide in the cytoplasm is relatively slow in part due to the rarity of two radical molecules coming into contact in a radical–radical recombination step; however, if nitric oxide diffuses into the mitochondria, where large amounts of oxygen and superoxide reside, the rate of nitric oxide autoxidation has been shown to increase dramatically contributing to a "lens effect" wherein nitric oxide and superoxide are focused into hydrophobic compartments further increasing the rate of autoxidation (Moller et al. 2007; Liu et al. 1998). This production of peroxynitrite (in the presence of CO2) induces protein nitration, covalently modified onto tyrosine side chains in the 3′ position resulting in the protein nitration product, 3-nitrotyrosine (3-NT) (Ischiropoulos 2009). Nitration of the 3′ position likely contributes to an interruption in protein signaling due to the ability of tyrosine to be phosphorylated on the 4′ hydroxyl group in specific target proteins (Feeney and Schoneich 2012).

Amyloid-β-induced oxidative stress hypothesis of AD and the importance of Met-35

The amyloid-β-induced oxidative stress hypothesis posits that amyloid-β, specifically Aβ$_{1-42}$, is primarily responsible

Table 2 Summary of signaling proteins discussed within the text, modifications identified, and the AD stage and/or brain region analyzed

Identified protein	Modifications
Glutamine synthase	PC
CRMP2	HNE, 3NT, PC, SNO
Alpha-enolase	HNE, PC, SNO
Pin1	PC
Gamma-SNAP	PC
Alpha-tubulin	HNE
Actin	HNE
Transition initiation factor alpha	HNE
Elongation factor Tu	HNE
Syntaxin-binding protein 1	PC
Carbonic anhydrase II	PC
Mitogen-activated kinase 1	PC
Alpha-INTERNEXIN	SNO
Glutamate dehydrogenase	SNO
Proenkephalin	SNO
Proopiomelanocortin	SNO
GFAP	SNO
Septin	SNO

Table 3 Summary of proteins involved in the proteasome or unfolded protein response discussed within the text, modifications identified, and the AD stage and/or brain region analyzed

Identified protein	Modifications
UCH L-1	PC
Cu/Zn-SOD	PC
Mn-SOD	HNE
HSPA8	3 NT, PC
HSP70	HNE, PC
Glutathione-S-transferase Mu	3NT
Multidrug-resistant protein-1	HNE
Multidrug-resistant protein-3	3NT
Peroxiredoxin 6	HNE, 3NT
Glutathione-S-transferase	HNE
Proteasome	HNE

in large part for the oxidative damage observed to take place in AD (Butterfield et al 2001; Markesbery 1997). Oxidative stress has long been associated with AD and MCI and has been found to associate with Aβ. As previously discussed, there are two primary forms of Aβ: $Aβ_{1-40}$ and $Aβ_{1-42}$, with $Aβ_{1-42}$ being found to be more neurotoxic and aggregate more quickly than the 1–40 proteolytic variant (Butterfield and Sultana 2011). The effect of $Aβ_{1-42}$ on the levels of intracellular ROS has been verified in a number of experiments by our laboratory and others using in vivo

and in vitro methods. For instance, $Aβ_{1-42}$ was added to 9- to 11-day-old primary hippocampal neuronal cultures which led to an increase in markers of oxidative stress and resulted in neurotoxicity (Yatin et al. 1999; Boyd-Kimball et al. 2004). Other studies have shown that this Aβ-induced oxidative stress may be mitigated through the use of free radical scavengers such as melatonin, estradiol, vitamin E, while more studies demonstrate that the neurotoxic effects of the $Aβ_{1-42}$ peptide were modulated specifically by vitamin E (Boyd-Kimball et al. 2004; Yatin et al. 2000; Quintanilla et al. 2005; Olivieri et al. 2001; Behl and Moosmann 2002). While these experiments demonstrate the neurotoxic effects of $Aβ_{1-42}$, the method of Aβ-induced ROS generation was as of then unclear. We have since provided evidence that suggests a major method of ROS generation by $Aβ_{1-42}$ is through the one-electron oxidation of the methionine-35 residue followed by lipid peroxidation, a process that involves a chain reaction (Fig. 2) (Butterfield and Boyd-Kimball 2005; Butterfield et al. 2007, 2010a, b). This mechanism is a way for a small free radical initiation step on $Aβ_{1-42}$ to be greatly amplified by continuous production of acyl-chain-resident C-centered free radicals that subsequently leads to production of HNE.

Redox proteomics of human samples

Brain samples from subjects diagnosed with MCI- or AD-related dementia are invaluable because of their absolute physiological relevance. While data from animal models provide valuable insight into disease progression, extrapolating the data for use in humans has proven to be difficult in large part due to the inherent physiological and biochemical differences. Moreover, it is important to maintain sample integrity with a low postmortem interval (PMI), as higher PMIs may result in protein degradation and oxidation before analysis can begin. At the University of Kentucky, autopsy-derived specimens are obtained with a very short PMI, usually between 2 and 4 h. This low PMI allows us to perform our studies, such as redox proteomics, using human samples as close to living brain as feasibly possible.

Proteomics itself is a global term for the study of the proteome, whether in its entirety or a specific portion. The objective of redox proteomics is to narrow this focus onto that of oxidatively/nitrosatively modified proteins with the ultimate goal of protein identification matched with oxidative modification. Our laboratory pioneered the establishment and utilization of redox proteomics in the study of AD and has contributed a great deal to the understanding of the diseased proteome in the various stagings of AD: PCAD, MCI, and AD. There are two primary methods for the employment of redox proteomics: the first being the gel-free enrichment of proteins which present oxidative

Fig. 2 Schematic illustration of our proposed schematic for the method by which Aβ oligomers insert into a bilayer and subsequently initiate lipid peroxidation through the one-electron oxidation of Met-35 of the Aβ$_{1-42}$ peptide

Oligomeric Aß Insertion into Membrane Bilayer

ILE-31
MET-35

One Electron Oxidation of Met-35

Lipid Peroxidation

Reactive Aldehyde Formation

modifications, while the second a gel-based global method (Butterfield et al. 2012). A non-gel method for redox proteomic analysis utilizes strong cation exchange and reverse-phase liquid chromatography and both mass spectrometry and tandem mass spectrometry (MS/MS). In the non-gel-based method, the proteins are digested in solution and peptides separated using nanoflow liquid chromatography where the separated peptides are subjected to automated MS identification.

In the gel-based method, samples are prepared accordingly to established protocols and the proteins separated in the first dimension according to their respective isoelectric points. Immediately following isoelectric separation, the proteins are run in the second dimension according to their migration rate. The two-dimensional separation yields distinct and isolated protein localizations within the gel which are ideally suited for comparison and identification. In order to determine the oxidatively modified proteins, the gels are first imaged and then transferred to a nitrocellulose membrane for immunochemical detection of the oxidative modification of interest on a 2-D western blot. The actual spot comparison is made using spot-matching software such as PD-Quest or Dimensional Delta 2D by comparing individual spot density to matched proteins. Once analysis is completed, identification of selected proteins is initiated through the excision of the target spot and in-gel trypsin digestion. The digested spots are then identified based on

their peptide mass fingerprint (PMF) through the use of either matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) mass spectrometry or sequencing of the tryptic peptides using electrospray ionization tandem mass spectrometry (ESI–MS/MS). ESI–MS/MS is especially useful due to the ability to select parental peptides to send through to an additional fragmentation which allows for an identification of the amino acid sequence and subsequently the tryptic peptide. Further, this technique has been developed to probe possible oxidatively modified sites or sites for other posttranslational modifications. The identification of the tryptic peptide is accomplished through the searching of peptide databases such as MASCOT and SEQUEST.

Oxidized brain proteins from subjects with AD and MCI gathered using redox proteomics

Energy metabolism

A prominent hallmark of AD and MCI is a marked decrease in the metabolism of glucose, primarily glycolysis, the tricarboxylic acid cycle (TCA), and the electron transport chain. Evidence of glucose utilization deficiency has been known for some time with data collected from fluorodeoxyglucose positron emission tomography (FDG-PET) scans

(Rapoport 1999). The importance of an impaired metabolic function in the brain is magnified by the fact that the brain consumes 30 % of inspired oxygen and 20 % of ingested glucose. Any impairment in glucose metabolism may have drastic effects to the overall health of the brain, and thus the organism. Redox proteomics has been able to shed some light on some possible reasons for this glucose utilization deficiency with the discovery of many proteins associated with metabolic processes being posttranslationally modified either by lipid conjugation or by reaction with ROS/RNS.

ATP synthase, an enzyme in the final step in the production of ATP from the electron transport chain, was found to be modified by HNE in the AD hippocampus, while α-enolase, aldolase, and aconitase were all found to be HNE-bound in the AD cortex (Perluigi et al. 2009). AD IPL was shown to have increased protein carbonylation of creatine kinase BB and α-enolase compared with age-matched controls, while AD hippocampus yielded carbonylated phosphoglycerate mutase 1, carbonic anhydrase II, triose phosphate isomerase (TPI), and α-enolase (Castegna et al. 2002a, b; Sultana et al. 2006a, b, c). In further studies, nitrated adducts of both α- and γ-enolase, TPI, and lactate dehydrogenase were found in AD IPL, while nitrated α-enolase, phosphoglycerate-3-dehydrogenase (GAPDH), ATP synthase alpha chain, and voltage-dependent anion channel (VDAC) were found in AD hippocampus (Sultana et al. 2006a, b, c; Castegna et al. 2003). Redox proteomics of familial AD (FAD) found specific increased carbonylation of γ-enolase (Butterfield et al. 2006).

Furthermore, redox proteomics of MCI cortex and hippocampus identified HNE-modified α-enolase as well as lactate dehydrogenase B (LDH-B), phosphoglycerate kinase (PGK), pyruvate kinase, and ATP synthase alpha chain (Reed et al. 2008). Nitration was observed of malate dehydrogenase (MDH), α-enolase, glucose-regulated protein precursor (GRP) and aldolase in MCI IPL, while α-enolase and MDH were found to be nitrated in MCI hippocampus (Sultana et al. 2007). Furthermore, protein carbonylation of α-enolase and pyruvate kinase M2 in MCI brain has also been reported (Butterfield et al. 2006). These findings of oxidatively modified proteins in MCI suggest that enzymes crucial to the normal functioning of energy metabolic pathways are affected in the early stages of AD, supplying evidence that corroborates the PET imaging discussed.

Enolase and its isoforms, which were found to be modified in the majority of studies mentioned, is specifically important to note as not only does it play a large role in the second stage of glycolysis in glucose metabolism, but recent research indicates it has a pleiotropic role in many other non-glycolytic functions such as in cellular signaling, activation of survival pathways, a neurotrophic factor, hypoxic stress protein, a transcription factor, and clearance

of Aβ (Butterfield and Lange 2009; Takei et al. 1991; Aaronson et al. 1995; Subramanian and Miller 2000). As discussed above, oxidative insult to a protein involved in a large number of systems may have a pronounced negative effect downstream, whether that be energy metabolism or cell signaling.

Signaling, structure, and neurotransmission

The primary function of the brain is to communicate with itself and all other bodily systems, and consequently proper functioning of cellular signaling and neurotransmission is of the utmost importance for the maintenance of a healthy brain. Likewise, the ability of the neuron to maintain its internal integrity while retaining the ability to guide the growth cone and form new synapses also is important to overall neuronal health. However, redox proteomic investigations demonstrated that many enzymes and proteins involved in cellular subsystems such as growth, axonal guidance and integrity, and neurotransmission have been oxidatively modified in AD and MCI brain.

Protein carbonylation of glutamine synthase, dihydropyrimidinase-related protein-2 also known as collapsin response mediator protein-2 (DRP-2 or CRMP2), and the pleiotropic α-enolase was observed in AD IPL, while carbonylation of the phosphorylation-specific peptidyl-prolyl cis/trans isomerase Pin1, CRMP2, α-enolase, and γ-SNAP was found in AD hippocampus when compared to age-matched controls (Sultana et al. 2006a, b, c; Castegna et al. 2002a, b). Being important in demonstrating that oxidative damage may have a significant impact on the ability of a protein to fulfill its normal function, this study also demonstrated that enzyme activities of Pin1, enolase, and carbonic anhydrase were all decreased (Sultana et al. 2006a, b, c). The oxidation of CRMP2 is notable as it is heavily involved in the control of axonal growth and overall neuroplasticity, so its modification may well contribute to the loss of synaptic integrity observed in AD. Pin1 is a regulatory isomerase of whose loss is implicated in nearly every pathogenic hallmark of AD, and is directly involved in amyloid-β-precursor protein (AβPP) processing and the phosphorylation status of protein-tau (Ma et al. 2012). Pin1 is also intricately involved in many stages of the cell cycle through direct contact with target proteins as well as indirect action through the regulation of important kinases and phosphatases (Keeney et al. 2012; Driver and Lu 2010; Lin et al. 2015). We recently reported that the active site Cys-113 residue is oxidatively modified to sulfonic acid in AD brain, and we posit that this modification may account for the decreased Pin1 activity we have observed in AD brain (Chen et al. 2015; Sultana et al. 2006a, b, c).

Carbonylation was not the only modification relating to signaling and structural proteins found in AD brain.

Secondary carbonylation, demonstrated by the identification of HNE-modified proteins, was observed for CRMP2 in AD hippocampus and α-enolase, and α-tubulin in AD cortex (Perluigi et al. 2009). In MCI hippocampus and cortex, redox proteomic identification of protein-bound HNE was found to affect α-enolase, actin, translation initiation factor-α, and elongation factor Tu, while experiments into the nitration of proteins in MCI hippocampus yielded nitrated CRMP2 (Reed et al. 2008; Sultana et al. 2007). Carbonylation of glutamine synthetase, Pin1, syntaxin-binding protein I, carbonic anhydrase II, and mitogen-activated protein kinase I was likewise identified in MCI brain (Butterfield et al. 2006; Sultana et al. 2009). Interestingly, within the entorhinal cortex of AD brain, S-nitrosylation of cysteine residues was reported to modify CRMP2, alpha-internexin, glutamate dehydrogenase, proenkephalin, proopiomelanocortin, α-enolase, glial fibrillary acidic protein (GFAP), and septin, which may suggest that glial cells around SPs present higher levels of nitrosylation of GFAP and may contribute to the pathogenesis of AD (Riederer et al. 2009).

Proteasome system and the oxidative response system

As discussed, oxidative insult to proteins mediated by free radicals is key in both normal aging and age-related diseases, and the clearance of damaged peptides from the cell serves as protection from non-functioning proteins and/or protein aggregation primarily due to the fact that most protein oxidation is non-reversible, aside from the action of carbonyl reductase (Perluigi et al. 2014). Left unchecked, protein oxidation may affect gene regulation and downstream protein expression, general cell signaling, apoptosis and necrosis, and protein turnover due to non- or dysfunctional protein regulators, which subsequently may lead to cell death (Butterfield et al. 2012). Moreover, because of the structural changes that oxidative damage may cause, protein aggregation is a likely end product, and such aggregation has been evidenced in neurodegenerative diseases such as amyotrophic lateral sclerosis with SOD1, Parkinson disease with α-synuclein, and AD with Aβ.

Two proteasome systems found to be important in AD pathology are the 20S proteasome and the 26S proteasome. The 26S proteasome, also known as the ubiquitin–proteasome system (UPS), degrades shortly lived or misfolded proteins (Forster et al. 2013). The target protein is first poly-ubiquitinylated through the concerted effort of E1 ubiquitin-activating enzymes, E2 ubiquitin-conjugating enzymes, and E3 ligases preceding the chaperone-mediated transport to the 26S proteasome complex for degradation. Just prior to entry, the enzyme ubiquitin carboxy-terminal hydrolase-1 (UCH L-1) cleaves the ubiquitin moieties from the target protein one at a time, allowing the target protein

to be degraded and preserving an active pool of ubiquitin for cellular usage (Forster et al. 2013; Kleiger and Mayor 2014).

The 20S proteasome is a ubiquitin-independent system and primarily degrades oxidatively modified, mutated, or aged proteins recognized by the 20S system due by the structural disorder inherent in the damaged proteins (Ben-Nissan and Sharon 2014; Hwang et al. 2011; Pickering and Davies 2012; Jung et al. 2013). Additionally, the 20S proteasome may degrade proteins which contain both intrinsically disordered regions (IDRs) and proteins containing intrinsically disordered sequences (IDPs) (Ben-Nissan and Sharon 2014; van der Lee et al. 2014; Dyson and Wright 2005). This function is especially important with concern to IDPs, as many function as regulator and signaling proteins in cell cycle control, growth control, and oncogenesis, and proper control over their protein levels is needed to prevent development of disease (Dyson and Wright 2005; Aiken et al. 2011). Therefore, properly functioning proteasomal systems are vital to the health of a cell, and disturbance of these systems may trigger catastrophic events leading to cell death through loss of control or protein aggregation.

Using redox proteomics, we found that UCH L-1 was carbonylated in AD brain, specifically AD IPL, AD hippocampus, and FAD IPL (Sultana et al. 2006a, b, c; Butterfield et al. 2006; Castegna et al. 2002a, b). These results were corroborated by others who also found oxidatively modified Cu/Zn-superoxide dismutase (Choi et al. 2004). An oxidatively modified and dysfunctional UCH-L1 poses a threat to the cell as ubiquitinylated proteins cannot enter the proteasome without first having their ubiquitin moieties hydrolyzed away from the ubiquitinylated protein. This bottleneck may lead to not only an accumulation of damaged and ubiquitinylated proteins and a loss of cellular signaling control if important short-lived regulators are not kept in check, but also a depletion of the ubiquitin pool since the fixed amount of ubiquitin is not recycled for reuse (Kleiger and Mayor 2014; Castegna et al. 2002a, b). Chaperone proteins and proteins involved in the unfolded protein response were also found to be oxidatively modified. Heat shock cognate 71 (HSPA8) was identified as being both carbonylated and specifically nitrated in AD IPL and MCI hippocampus, respectively (Sultana et al. 2007; Castegna et al. 2002a, b). Heat-shock protein 70 (HSP70) was also reported to be carbonylated and HNE-modified in MCI brain (Reed et al. 2008; Sultana et al. 2009). Glutathione-S-transferase Mu (GST-M) and multidrug-resistant protein 3 (MRP3) were found to be nitrated in MCI IPL, while peroxiredoxin 6 (PR VI) was found nitrated in MCI hippocampus and HNE-bound in AD cortex (Perluigi et al. 2009; Sultana et al. 2007). Mn-SOD was found to be covalently modified by HNE in the AD hippocampus (Perluigi et al. 2009). GST, MRP-1, and GSH were all found to

be HNE-modified, and an increase in HNE protein adducts was reported (Lovell et al. 1998; Sultana and Butterfield 2004). The proteasome itself has also been reported to be the target of oxidative injury as HNE, and neuroprostane conjugation was found in the brain of both MCI and AD tissues (Cecarini et al. 2007). We posit that the oxidation and modification of the aforementioned proteins, which play large roles in the defense against such oxidative insult, protein turnover/degradation, and protein folding, likely contribute to disease pathogenesis in the progression of AD.

Conclusion

Redox proteomics studies of human brain have provided a wealth of information in regard to the molecular progression of AD and MCI, as well as a number of other detrimental and degenerative diseases. Providing information about the molecular degeneration of the disease enables others more to use that knowledge to not only improve upon existing treatments, but develop new ones by targeting specific proteins key to AD progression, which have been found to be oxidatively modified and dysfunctional. Not only are eventual treatments an end goal, but the identification of potential protein biomarkers for the successful and early detection of AD and MCI are critical in delaying AD onset among the coming tide of patients with AD dementia that are being predicted. Research has shown that by the time AD presents itself, much of the damage has already occured, which makes the need for early biomarker identification an absolute necessity. Here, we have shown evidences from a multitude of studies demonstrating that systems vital to the health of the brain are impaired by way of oxidative insult through ROS/RNS and reactive aldehyde-mediated conjugation. We posit that the damage to these proteins leads to deficiencies in systems important to the brain, such as energy metabolism, cell signaling, neurotransmitter release, and the proteasome, which may lead to the progression and pathogenesis of AD.

References

Aaronson RM, Graven KK, Tucci M, McDonald RJ, Farber HW (1995) Non-neuronal enolase is an endothelial hypoxic stress protein. J Biol Chem 270:27752–27757

Adam-Vizi V (2005) Production of reactive oxygen species in brain mitochondria: contribution by electron transport chain and non-electron transport chain sources. Antioxid Redox Signal. doi:10.1089/ars.2005.7.1140

Aiken CT, Kaake RM, Wang X, Huang L (2011) Oxidative stress-mediated regulation of proteasome complexes. Mol Cell Proteomics R110:006924. doi:10.1074/mcp.M110.006924

Aluise CD, Robinson RA, Cai J, Pierce WM, Markesbery WR, Butterfield DA (2011) Redox proteomics analysis of brains from subjects with amnestic mild cognitive impairment compared to brains from subjects with preclinical Alzheimer's disease: insights into memory loss in MCI. J Alzheimer's Dis. doi:10.3233/JAD-2010-101083

Andreadis A, Brown WM, Kosik KS (1992) Structure and novel exons of the human tau gene. Biochemistry 10626–10633

Bader Lange ML, St Clair D, Markesbery WR, Studzinski CM, Murphy MP, Butterfield DA (2010) Age-related loss of phospholipid asymmetry in APP(NLh)/APP(NLh) x PS-1(P264L)/PS-1(P264L) human double mutant knock-in mice: relevance to Alzheimer disease. Neurobiol Dis. doi:10.1016/j.nbd.2010.01.004

Behl C, Moosmann B (2002) Oxidative nerve cell death in Alzheimer's disease and stroke: antioxidants as neuroprotective compounds. Biol Chem. doi:10.1515/BC.2002.053

Ben-Nissan G, Sharon M (2014) Regulating the 20S proteasome ubiquitin-independent degradation pathway. Biomolecules. doi:10.3390/biom4030862

Boyd-Kimball D, Mohmmad Abdul H, Reed T, Sultana R, Butterfield DA (2004) Role of phenylalanine 20 in Alzheimer's amyloid beta-peptide (1–42)-induced oxidative stress and neurotoxicity. Chem Res Toxicol. doi:10.1021/tx049796w

Braak H, Braak E (1997) Staging of Alzheimer-related cortical destruction. Int Psychogeriatr 257–261 **(discussion 269–272)**

Bradley MA, Markesbery WR, Lovell MA (2010) Increased levels of 4-hydroxynonenal and acrolein in the brain in preclinical Alzheimer disease. Free Rad Biol Med. doi:10.1016/j.freeradbiomed.2010.02.016

Butterfield DA (2002) Amyloid beta-peptide (1–42)-induced oxidative stress and neurotoxicity: implications for neurodegeneration in Alzheimer's disease brain. A review. Free Rad Res 36:1307–1313

Butterfield DA, Boyd-Kimball D (2005) The critical role of methionine 35 in Alzheimer's amyloid beta-peptide (1-42)-induced oxidative stress and neurotoxicity. Biochim Biophys Acta. doi:10.1016/j.bbapap.2004.10.014

Butterfield DA, Lange ML (2009) Multifunctional roles of enolase in Alzheimer's disease brain: beyond altered glucose metabolism. J Neurochem. doi:10.1111/j.1471-4159.2009.06397.x

Butterfield DA, Sultana R (2011) Methionine-35 of abeta(1-42): importance for oxidative stress in Alzheimer disease. J Amino Acids. doi:10.4061/2011/198430

Butterfield DA, Drake J, Pocernich C, Castegna A (2001) Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide. Trends Mol Med 7:548–554

Butterfield DA, Poon HF, St Clair D, Keller JN, Pierce WM, Klein JB, Markesbery WR (2006) Redox proteomics identification of oxidatively modified hippocampal proteins in mild cognitive impairment: insights into the development of Alzheimer's disease. Neurobiol Dis. doi:10.1016/j.nbd.2005.11.002

Butterfield DA, Reed T, Newman SF, Sultana R (2007) Roles of amyloid beta-peptide-associated oxidative stress and brain protein modifications in the pathogenesis of Alzheimer's disease and mild cognitive impairment. Free Rad Biol Med. doi:10.1016/j.freeradbiomed.2007.05.037

Butterfield DA, Bader Lange ML, Sultana R (2010a) Involvements of the lipid peroxidation product, HNE, in the pathogenesis and progression of Alzheimer's disease. Biochim Biophys Acta. doi:10.1016/j.bbalip.2010.02.005

Butterfield DA, Galvan V, Lange MB, Tang H, Sowell RA, Spilman P, Bredesen DE (2010b) In vivo oxidative stress in brain of Alzheimer disease transgenic mice: Requirement for methionine 35 in amyloid beta-peptide of APP. Free Rad Biol Med. doi:10.1016/j.freeradbiomed.2009.10.035

Butterfield DA, Perluigi M, Reed T, Muharib T, Hughes CP, Robinson RA, Sultana R (2012) Redox proteomics in selected neurodegenerative disorders: from its infancy to future applications. Antioxid Redox Signal. doi:10.1089/ars.2011.4109

Butterfield DA, Swomley AM, Sultana R (2013) Amyloid beta-peptide (1-42)-induced oxidative stress in Alzheimer disease: importance in disease pathogenesis and progression. Antioxid Redox Signal. doi:10.1089/ars.2012.5027

Calabrese V, Lodi R, Tonon C, D'Agata V, Sapienza M, Scapagnini G, Butterfield DA (2005) Oxidative stress, mitochondrial dysfunction and cellular stress response in Friedreich's ataxia. J Neurol Sci. doi:10.1016/j.jns.2005.03.012

Castegna A, Aksenov M, Thongboonkerd V, Klein JB, Pierce WM, Booze R, Butterfield DA (2002a) Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part II: dihydropyrimidinase-related protein 2, alpha-enolase and heat shock cognate 71. J Neurochem 82:1524–1532

Castegna A, Aksenov M, Aksenova M, Thongboonkerd V, Klein JB, Pierce WM, Butterfield DA (2002b) Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part I: creatine kinase BB, glutamine synthase, and ubiquitin carboxy-terminal hydrolase L-1. Free Rad Biol Med 33:562–571

Castegna A, Thongboonkerd V, Klein JB, Lynn B, Markesbery WR, Butterfield DA (2003) Proteomic identification of nitrated proteins in Alzheimer's disease brain. J Neurochem 1394–1401

Castegna A, Lauderback CM, Mohmmad-Abdul H, Butterfield DA (2004) Modulation of phospholipid asymmetry in synaptosomal membranes by the lipid peroxidation products, 4-hydroxynonenal and acrolein: implications for Alzheimer's disease. Brain Res. doi:10.1016/j.brainres.2004.01.036

Cecarini V, Ding Q, Keller JN (2007) Oxidative inactivation of the proteasome in Alzheimer's disease. Free Rad Res. doi:10.1080/10715760701286159

Chen CH, Li W, Sultana R, You MH, Kondo A, Shahpasand K, Lu KP (2015) Pin1 cysteine-113 oxidation inhibits its catalytic activity and cellular function in Alzheimer's disease. Neurobiol Dis. doi:10.1016/j.nbd.2014.12.027

Choi J, Levey AI, Weintraub ST, Rees HD, Gearing M, Chin LS, Li L (2004) Oxidative modifications and down-regulation of ubiquitin carboxyl-terminal hydrolase L1 associated with idiopathic Parkinson's and Alzheimer's diseases. J Biol Chem. doi:10.1074/jbc.M314124200

Dasuri K, Zhang L, Keller JN (2013) Oxidative stress, neurodegeneration, and the balance of protein degradation and protein synthesis. Free Rad Biol Med. doi:10.1016/j.freeradbiomed.2012.09.016

Dean RT, Fu S, Stocker R Davies MJ (1997) Biochemistry and pathology of radical-mediated protein oxidation. Biochem J 1–18

Driver JA, Lu KP (2010) Pin1: a new genetic link between Alzheimer's disease, cancer and aging. Curr Aging Sci 3:158–165

Dunlop RA, Brunk UT, Rodgers KJ (2009) Oxidized proteins: mechanisms of removal and consequences of accumulation. IUBMB life. doi:10.1002/iub.189

Dyson HJ, Wright PE (2005) Intrinsically unstructured proteins and their functions. Nat Rev Mol Cell Biol. doi:10.1038/nrm1589

Feeney MB, Schoneich C (2012) Tyrosine modifications in aging. Antioxid Redox Signal. doi:10.1089/ars.2012.4595

Forster F, Unverdorben P, Sledz P, Baumeister W (2013) Unveiling the long-held secrets of the 26S proteasome. Structure. doi:10.1016/j.str.2013.08.010

Friedland-Leuner K, Stockburger C, Denzer I, Eckert GP, Muller WE (2014) Mitochondrial dysfunction: cause and consequence of Alzheimer's disease. Prog Mol Biol Transl Sci. doi:10.1016/B978-0-12-394625-6.00007-6

Glabe C (2001) Intracellular mechanisms of amyloid accumulation and pathogenesis in Alzheimer's disease. J Mol Neurosci. doi:10.1385/JMN:17:2:137

Glabe CC (2005) Amyloid accumulation and pathogensis of Alzheimer's disease: significance of monomeric, oligomeric and fibrillar Abeta. Sub-cell Biochem 38:167–177

Halliwell B (2012) Free radicals and antioxidants: updating a personal view. Nutr Rev. doi:10.1111/j.1753-4887.2012.00476.x

Halliwell B, Gutteridge JM (1984) Oxygen toxicity, oxygen radicals, transition metals and disease. Biochem J 1–14

Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA (2003) Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol. doi:10.1001/archneur.60.8.1119

Hernandez-Saavedra D, McCord JM (2007) Evolution and free radicals. Importance of oxidative stress in human pathology. Revista medica del Instituto Mexicano del Seguro Social 45:477–484

Hwang J, Winkler L, Kalejta RF (2011) Ubiquitin-independent proteasomal degradation during oncogenic viral infections. Biochim Biophys Acta. doi:10.1016/j.bbcan.2011.05.005

Indo HP, Yen HC, Nakanishi I, Matsumoto K, Tamura M, Nagano Y, Majima HJ (2015) A mitochondrial superoxide theory for oxidative stress diseases and aging. J Clin Biochem Nutr. doi:10.3164/jcbn.14-42

Ischiropoulos H (2009) Protein tyrosine nitration–an update. Arch Biochem Biophys. doi:10.1016/j.abb.2008.10.034

Jicha GA, Parisi JE, Dickson DW, Johnson K, Cha R, Ivnik RJ, Petersen RC (2006) Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia. Arch Neurol. doi:10.1001/archneur.63.5.674

Jung T, Hohn A, Grune T (2013) The proteasome and the degradation of oxidized proteins: Part II - protein oxidation and proteasomal degradation. Redox Biol. doi:10.1016/j.redox.2013.12.008

Keeney JT, Swomley AM, Harris JL, Fiorini A, Mitov MI, Perluigi M, Butterfield DA (2012) Cell cycle proteins in brain in mild cognitive impairment: insights into progression to Alzheimer disease. Neurotox Res. doi:10.1007/s12640-011-9287-2

Kleiger G, Mayor T (2014) Perilous journey: a tour of the ubiquitin-proteasome system. Trends Cell Biol. doi:10.1016/j.tcb.2013.12.003

Levine RL, Williams JA, Stadtman ER, Shacter E (1994) Carbonyl assays for determination of oxidatively modified proteins. Methods Enzymol 233:346–357

Lin CH, Li HY, Lee YC, Calkins MJ, Lee KH, Yang CN, Lu PJ (2015) Landscape of Pin1 in the cell cycle. Exp Biol Med. doi:10.1177/1535370215570829

Liu X, Miller MJ, Joshi MS, Thomas DD, Lancaster Jr JR (1998) Accelerated reaction of nitric oxide with O2 within the hydrophobic interior of biological membranes. Proc Natl Acad Sci USA 95:2175–2179

Lovell MA, Xie C, Markesbery WR (1998) Decreased glutathione transferase activity in brain and ventricular fluid in Alzheimer's disease. Neurology 51:1562–1566

Lovell MA, Xie C, Markesbery WR (2001) Acrolein is increased in Alzheimer's disease brain and is toxic to primary hippocampal cultures. Neurobiol Aging 22:187–194

Ma SL, Pastorino L, Zhou XZ, Lu KP (2012) Prolyl isomerase Pin1 promotes amyloid precursor protein (APP) turnover by inhibiting glycogen synthase kinase-3beta (GSK3beta) activity: novel mechanism for Pin1 to protect against Alzheimer disease. J Biol Chem. doi:10.1074/jbc.C111.298596

Markesbery WR (1997) Oxidative stress hypothesis in Alzheimer's disease. Free Rad Biol Med 23:134–147

Markesbery WR, Kryscio RJ, Lovell MA, Morrow JD (2005) Lipid peroxidation is an early event in the brain in amnestic mild cognitive impairment. Ann Neurol. doi:10.1002/ana.20629

McCarty MF (2006) Down-regulation of microglial activation may represent a practical strategy for combating neurodegenerative disorders. Med Hypotheses. doi:10.1016/j.mehy.2006.01.013

Moh C, Kubiak JZ, Bajic VP, Zhu X, Smith MA, Lee HG (2011) Cell cycle deregulation in the neurons of Alzheimer's disease. Result Probl Cell Differ. doi:10.1007/978-3-642-19065-0_23

Moller MN, Li Q, Lancaster JR Jr, Denicola A (2007) Acceleration of nitric oxide autoxidation and nitrosation by membranes. IUBMB life. doi:10.1080/15216540701311147

Nakamura T, Prikhodko OA, Pirie E, Nagar S, Akhtar MW, Oh CK, Lipton SA (2015) Aberrant protein S-nitrosylation contributes to the pathophysiology of neurodegenerative diseases. Neurobiol Dis. doi:10.1016/j.nbd.2015.03.017

Nourazarian AR, Kangari P, Salmaninejad A (2014) Roles of oxidative stress in the development and progression of breast cancer. Asian Pac J Cancer Prev 15:4745–4751

Oddo S (2008) The ubiquitin-proteasome system in Alzheimer's disease. J Cell Mol Med. doi:10.1111/j.1582-4934.2008.00276.x

Olivieri G, Hess C, Savaskan E, Ly C, Meier F, Baysang G, Muller-Spahn F (2001) Melatonin protects SHSY5Y neuroblastoma cells from cobalt-induced oxidative stress, neurotoxicity and increased beta-amyloid secretion. J Pineal Res 31:320–325

Perluigi M, Sultana R, Cenini G, Di Domenico F, Memo M, Pierce WM, Butterfield DA (2009) Redox proteomics identification of 4-hydroxynonenal-modified brain proteins in Alzheimer's disease: Role of lipid peroxidation in Alzheimer's disease pathogenesis. Proteomics Clin Appl. doi:10.1002/prca.200800161

Perluigi M, Coccia R, Butterfield DA (2012) 4-Hydroxy-2-nonenal, a reactive product of lipid peroxidation, and neurodegenerative diseases: a toxic combination illuminated by redox proteomics studies. Antioxid Redox Signal. doi:10.1089/ars.2011.4406

Perluigi M, Swomley AM, Butterfield DA (2014) Redox proteomics and the dynamic molecular landscape of the aging brain. Ageing Res Rev. doi:10.1016/j.arr.2013.12.005

Pickering AM, Davies KJ (2012) Degradation of damaged proteins: the main function of the 20S proteasome. Prog Mol Biol Transl Sci. doi:10.1016/B978-0-12-397863-9.00006-7

Quintanilla RA, Munoz FJ, Metcalfe MJ, Hitschfeld M, Olivares G, Godoy JA, Inestrosa NC (2005) Trolox and 17beta-estradiol protect against amyloid beta-peptide neurotoxicity by a mechanism that involves modulation of the Wnt signaling pathway. J Biol Chem. doi:10.1074/jbc.M411936200

Rapoport SI (1999) In vivo PET imaging and postmortem studies suggest potentially reversible and irreversible stages of brain metabolic failure in Alzheimer's disease. Eur Arch Psychiatry Clin Neurosci 893:46–55

Reed T, Perluigi M, Sultana R, Pierce WM, Klein JB, Turner DM, Butterfield DA (2008) Redox proteomic identification of 4-hydroxy-2-nonenal-modified brain proteins in amnestic mild cognitive impairment: insight into the role of lipid peroxidation in the progression and pathogenesis of Alzheimer's disease. Neurobiol Dis. doi:10.1016/j.nbd.2007.12.007

Riederer IM, Schiffrin M, Kovari E, Bouras C, Riederer BM (2009) Ubiquitination and cysteine nitrosylation during aging and Alzheimer's disease. Brain Res Bull. doi:10.1016/j.brainresbull.2009.04.018

Sayre LM, Zelasko DA, Harris PL, Perry G, Salomon RG, Smith MA (1997) 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease. J Neurochem 68:2092–2097

Shinde UA, Mehta AA, Goyal RK (2000) Nitric oxide: a molecule of the millennium. Indian J Exp Biol 38:201–210

Stadtman ER, Levine RL (2000) Protein oxidation. Ann Ny Acad Sci 899:191–208

Subramanian A, Miller DM (2000) Structural analysis of alpha-enolase. Mapping the functional domains involved in down-regulation of the c-myc protooncogene. J Biol Chem 275:5958–5965

Sultana R, Butterfield DA (2004) Oxidatively modified GST and MRP1 in Alzheimer's disease brain: implications for accumulation of reactive lipid peroxidation products. Neurochem Res 29:2215–2220

Sultana R, Boyd-Kimball D, Poon HF, Cai J, Pierce WM, Klein JB, Butterfield DA (2006a) Redox proteomics identification of oxidized proteins in Alzheimer's disease hippocampus and cerebellum: an approach to understand pathological and biochemical alterations in AD. Neurobiol Aging. doi:10.1016/j.neurobiolaging.2005.09.021

Sultana R, Poon HF, Cai J, Pierce WM, Merchant M, Klein JB, Butterfield DA (2006b) Identification of nitrated proteins in Alzheimer's disease brain using a redox proteomics approach. Neurobiol Dis. doi:10.1016/j.nbd.2005.10.004

Sultana R, Boyd-Kimball D, Poon HF, Cai J, Pierce WM, Klein JB, Butterfield DA (2006c) Oxidative modification and down-regulation of Pin1 in Alzheimer's disease hippocampus: a redox proteomics analysis. Neurobiol Aging. doi:10.1016/j.neurobiolaging.2005.05.005

Sultana R, Reed T, Perluigi M, Coccia R, Pierce WM, Butterfield DA (2007) Proteomic identification of nitrated brain proteins in amnestic mild cognitive impairment: a regional study. J Cell Mol Med. doi:10.1111/j.1582-4934.2007.00065.x

Sultana R, Perluigi M, Butterfield DA (2009) Oxidatively modified proteins in Alzheimer's disease (AD), mild cognitive impairment and animal models of AD: role of Abeta in pathogenesis. Acta Neuropathol. doi:10.1007/s00401-009-0517-0

Suzuki YJ, Carini M, Butterfield DA (2010) Protein carbonylation. Antioxid Redox Signal. doi:10.1089/ars.2009.2887

Takei N, Kondo J, Nagaike K, Ohsawa K, Kato K, Kohsaka S (1991) Neuronal survival factor from bovine brain is identical to neuron-specific enolase. J Neurochem 57:1178–1184

Tangvarasittichai S (2015) Oxidative stress, insulin resistance, dyslipidemia and type 2 diabetes mellitus. World J Diabetes. doi:10.4239/wjd.v6.i3.456

Tu S, Okamoto S, Lipton SA, Xu H (2014) Oligomeric abeta-induced synaptic dysfunction in Alzheimer's disease. Mol Neurodegener. doi:10.1186/1750-1326-9-48

Uttara B, Singh AV, Zamboni P, Mahajan RT (2009) Oxidative stress and neurodegenerative diseases: a review of upstream and downstream antioxidant therapeutic options. Curr Neuropharmacol. doi:10.2174/157015909787602823

Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J (2007) Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol. doi:10.1016/j.biocel.2006.07.001

van der Lee R, Buljan M, Lang B, Weatheritt RJ, Daughdrill GW, Dunker AK, Babu MM (2014) Classification of intrinsically disordered regions and proteins. Chem Rev. doi:10.1021/cr400525m

Walsh DM, Selkoe DJ (2004) Oligomers on the brain: the emerging role of soluble protein aggregates in neurodegeneration. Protein Pept Lett 11:213–228

Wang X, Kettenhofen NJ, Shiva S, Hogg N, Gladwin MT (2008) Copper dependence of the biotin switch assay: modified assay for measuring cellular and blood nitrosated proteins. Free Rad Biol Med. doi:10.1016/j.freeradbiomed.2007.12.032

Wilkins HM, Carl SM, Greenlief AC, Festoff BW, Swerdlow RH (2014) Bioenergetic dysfunction and inflammation in Alzheimer's disease: a possible connection. Front Aging Neurosci. doi:10.3389/fnagi.2014.00311

Williamson KS, Gabbita SP, Mou S, West M, Pye QN, Markesbery WR, Hensley K (2002) The nitration product 5-nitro-gamma-tocopherol is increased in the Alzheimer brain. Nitric oxide Biol Chem. doi:10.1006/niox.2001.0399

Xu W, Charles IG, Moncada S, Gorman P, Sheer D, Liu L, Emson P (1994) Mapping of the genes encoding human inducible and endothelial nitric oxide synthase (NOS2 and NOS3) to the

pericentric region of chromosome 17 and to chromosome 7, respectively. Genomics. doi:10.1006/geno.1994.1286

Yao Y, Zhukareva V, Sung S, Clark CM, Rokach J, Lee VM, Pratico D (2003) Enhanced brain levels of 8,12-iso-iPF2alpha-VI differentiate AD from frontotemporal dementia. Neurology 61:475–478

Yatin SM, Varadarajan S, Link CD, Butterfield DA (1999) In vitro and in vivo oxidative stress associated with Alzheimer's amyloid beta-peptide (1–42). Neurobiol Aging 20:325–330 (discussion 339–342)

Yatin SM, Varadarajan S, Butterfield DA (2000) Vitamin E prevents Alzheimer's amyloid beta-peptide (1–42)-induced neuronal protein oxidation and reactive oxygen species production. J Alzheimer's Dis 123–131